Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL

Essex Investment Management Co. LLC raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 3,670.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 45,625 shares of the biotechnology company’s stock after purchasing an additional 44,415 shares during the quarter. Essex Investment Management Co. LLC’s holdings in Exelixis were worth $1,884,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Norges Bank purchased a new stake in shares of Exelixis in the second quarter worth about $122,099,000. Qube Research & Technologies Ltd lifted its holdings in Exelixis by 120.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock valued at $134,306,000 after acquiring an additional 1,665,110 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Exelixis by 42.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after purchasing an additional 1,580,567 shares in the last quarter. Allianz Asset Management GmbH grew its stake in shares of Exelixis by 153.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after purchasing an additional 1,490,520 shares during the period. Finally, Prudential Financial Inc. increased its holdings in shares of Exelixis by 776.8% during the 2nd quarter. Prudential Financial Inc. now owns 1,468,865 shares of the biotechnology company’s stock valued at $64,740,000 after purchasing an additional 1,301,330 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported Q4 EPS above consensus (reported $0.94 vs. estimates around $0.74–$0.77), reflecting margin improvement and stronger profitability year‑over‑year. Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Balance sheet & cash flow strength: operating cash generation and cash balances improved materially (cash and equivalents rose, strong operating cash flow), which supports reinvestment and pipeline funding. Exelixis (EXEL) Releases Q4 2025 Earnings
• Positive Sentiment: Analyst support: William Blair and other firms have reiterated bullish stances / buy ratings, citing solid execution and advancing pipeline that underpin 2026 earnings power. Analyst backing can buoy sentiment even after mixed results. Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
• Neutral Sentiment: Corporate update / outlook: Management presented a slide deck and described progress on the cabozantinib franchise and clinical milestones, positioning the company for growth in 2026 — an update investors will parse for timing of launches and label expansions. Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Positive media/valuation mentions: Exelixis surfaced in value/PEG screens and retail pieces highlighting it as a sub‑$50 healthcare pick, which may attract long‑only and retail interest. 4 Discounted PEG Value Stocks to Boost Your Portfolio’s Health
• Negative Sentiment: Revenue shortfall vs. some estimates: total Q4 revenue rose year‑over‑year but came in below certain consensus figures (~$598.7M reported vs. higher street estimates), which likely tempered upside from the EPS beat. Exelixis (EXEL) Releases Q4 2025 Earnings
• Negative Sentiment: Insider selling & mixed price targets: recent filings show several insider sales and a wide range of analyst targets (some low), which can create caution among investors despite overall bullish coverage. Exelixis (EXEL) Releases Q4 2025 Earnings
• Neutral Sentiment: Short‑interest data in the newsfeed appears garbled/insignificant; it is not a clear driver in this update. (No reliable days‑to‑cover signal provided.)

Wall Street Analysts Forecast Growth

EXEL has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. UBS Group set a $41.00 price target on Exelixis in a research note on Monday, January 5th. Barclays increased their price target on Exelixis from $41.00 to $44.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Finally, Wolfe Research began coverage on Exelixis in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $46.16.

Insider Transactions at Exelixis

In other news, EVP Patrick J. Haley sold 34,187 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $41.88, for a total transaction of $1,431,751.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders sold 72,230 shares of company stock worth $3,046,923. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Stock Down 2.2%

Shares of NASDAQ:EXEL opened at $42.98 on Wednesday. Exelixis, Inc. has a 52-week low of $32.38 and a 52-week high of $49.62. The stock has a market cap of $11.52 billion, a P/E ratio of 18.14, a PEG ratio of 0.74 and a beta of 0.42. The business has a fifty day moving average of $43.69 and a two-hundred day moving average of $40.92.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.55 EPS. On average, equities analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.